

Nathan J Cherrington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2318134/publications.pdf>

Version: 2024-02-01

101
papers

4,657
citations

81900

39
h-index

106344

65
g-index

101
all docs

101
docs citations

101
times ranked

5192
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2087-2094. | 3.3 | 269 |
| 2 | Organ Distribution of Multidrug Resistance Proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and Hepatic Induction of Mrp3 by Constitutive Androstane Receptor Activators in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 97-104. | 2.5 | 206 |
| 3 | Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. <i>Amino Acids</i> , 2015, 47, 603-615. | 2.7 | 175 |
| 4 | Gender-Specific and Developmental Influences on the Expression of Rat Organic Anion Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 145-151. | 2.5 | 173 |
| 5 | Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2010, 38, 2293-2301. | 3.3 | 157 |
| 6 | Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. <i>Toxicology and Applied Pharmacology</i> , 2013, 268, 132-140. | 2.8 | 153 |
| 7 | LIPOPOLYSACCHARIDE-MEDIATED REGULATION OF HEPATIC TRANSPORTER mRNA LEVELS IN RATS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 734-741. | 3.3 | 142 |
| 8 | Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1954-1960. | 3.3 | 141 |
| 9 | Tissue Distribution and Chemical Induction of Multiple Drug Resistance Genes in Rats. <i>Drug Metabolism and Disposition</i> , 2002, 30, 838-844. | 3.3 | 138 |
| 10 | Drug metabolism alterations in nonalcoholic fatty liver disease. <i>Drug Metabolism Reviews</i> , 2011, 43, 317-334. | 3.6 | 136 |
| 11 | Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. <i>Toxicology and Applied Pharmacology</i> , 2008, 226, 74-83. | 2.8 | 134 |
| 12 | Variations in ATP-Binding Cassette Transporter Regulation during the Progression of Human Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2395-2402. | 3.3 | 122 |
| 13 | Induction of Drug-Metabolizing Enzymes by Garlic and Allyl Sulfide Compounds via Activation of Constitutive Androstane Receptor and Nuclear Factor E2-Related Factor 2. <i>Drug Metabolism and Disposition</i> , 2007, 35, 995-1000. | 3.3 | 117 |
| 14 | Differential Expression of Mouse Hepatic Transporter Genes in Response to Acetaminophen and Carbon Tetrachloride. <i>Toxicological Sciences</i> , 2005, 83, 44-52. | 3.1 | 110 |
| 15 | XENOBIOTIC AND ENDOBIOTIC TRANSPORTER MRNA EXPRESSION IN THE BLOOD-TESTIS BARRIER. <i>Drug Metabolism and Disposition</i> , 2005, 33, 182-189. | 3.3 | 100 |
| 16 | Drug-Metabolizing Enzyme and Transporter Expression in a Mouse Model of Diabetes and Obesity. <i>Molecular Pharmaceutics</i> , 2008, 5, 77-91. | 4.6 | 99 |
| 17 | Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. <i>European Journal of Pharmacology</i> , 2009, 613, 119-127. | 3.5 | 98 |
| 18 | Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2013, 41, 554-561. | 3.3 | 93 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. <i>Toxicology</i> , 2008, 250, 82-88. | 4.2 | 86 |
| 20 | Tissue Expression, Ontogeny, and Inducibility of Rat Organic Anion Transporting Polypeptide 4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 551-560. | 2.5 | 85 |
| 21 | Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1970-1978. | 3.3 | 84 |
| 22 | Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. <i>Liver International</i> , 2017, 37, 1074-1081. | 3.9 | 68 |
| 23 | Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease. <i>Oncotarget</i> , 2017, 8, 63370-63381. | 1.8 | 68 |
| 24 | Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 637-647. | 2.6 | 67 |
| 25 | INDUCTION OF MULTIDRUG RESISTANCE PROTEIN 3 (MRP3) IN VIVO IS INDEPENDENT OF CONSTITUTIVE ANDROSTANE RECEPTOR. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1315-1319. | 3.3 | 64 |
| 26 | Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. <i>Life Sciences</i> , 2008, 83, 59-64. | 4.3 | 63 |
| 27 | Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models. <i>Drug Metabolism and Disposition</i> , 2014, 42, 586-595. | 3.3 | 55 |
| 28 | Altered Regulation of Hepatic Efflux Transporters Disrupts Acetaminophen Disposition in Pediatric Nonalcoholic Steatohepatitis. <i>Drug Metabolism and Disposition</i> , 2015, 43, 829-835. | 3.3 | 55 |
| 29 | Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis. <i>Drug Metabolism and Disposition</i> , 2012, 40, 450-460. | 3.3 | 54 |
| 30 | Increased Susceptibility to Methotrexate-Induced Toxicity in Nonalcoholic Steatohepatitis. <i>Toxicological Sciences</i> , 2014, 142, 45-55. | 3.1 | 53 |
| 31 | Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. <i>Cell Stress and Chaperones</i> , 2006, 11, 356. | 2.9 | 53 |
| 32 | Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. <i>Archives of Toxicology</i> , 2008, 82, 959-964. | 4.2 | 50 |
| 33 | The Nrf2 Activator Oltipraz Also Activates the Constitutive Androstane Receptor. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1716-1721. | 3.3 | 45 |
| 34 | Synergistic interaction between genetics and disease on pravastatin disposition. <i>Journal of Hepatology</i> , 2014, 61, 139-147. | 3.7 | 44 |
| 35 | Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1642-1650. | 3.3 | 43 |
| 36 | Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 462-470. | 2.5 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. <i>Obesity</i> , 2017, 25, 1069-1076. | 3.0 | 41 |
| 38 | Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. <i>Journal of Biochemical and Molecular Toxicology</i> , 2007, 21, 216-220. | 3.0 | 40 |
| 39 | Alcohol Cirrhosis Alters Nuclear Receptor and Drug Transporter Expression in Human Liver. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1148-1155. | 3.3 | 40 |
| 40 | Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. <i>Journal of Applied Toxicology</i> , 2014, 34, 726-732. | 2.8 | 40 |
| 41 | Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2014, 59, 365-374. | 2.3 | 39 |
| 42 | Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 452-458. | 2.5 | 39 |
| 43 | Alcohol Metabolism in the Progression of Human Nonalcoholic Steatohepatitis. <i>Toxicological Sciences</i> , 2018, 164, 428-438. | 3.1 | 35 |
| 44 | A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Spragueâ€Dawley Rats. <i>Journal of Proteome Research</i> , 2020, 19, 3326-3339. | 3.7 | 35 |
| 45 | Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. <i>Molecular Pharmacology</i> , 2021, 100, 548-557. | 2.3 | 32 |
| 46 | Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 349-360. | 3.3 | 30 |
| 47 | Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. <i>Diabetes</i> , 2015, 64, 3305-3313. | 0.6 | 29 |
| 48 | Basolateral Uptake of Nucleosides by Sertoli Cells Is Mediated Primarily by Equilibrative Nucleoside Transporter 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 121-129. | 2.5 | 27 |
| 49 | Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH. <i>Toxicological Sciences</i> , 2018, 161, 23-33. | 3.1 | 25 |
| 50 | The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G48-G56. | 3.4 | 24 |
| 51 | Localization of Multidrug Resistance-Associated Proteins along the Blood-Testis Barrier in Rat, Macaque, and Human Testis. <i>Drug Metabolism and Disposition</i> , 2014, 42, 89-93. | 3.3 | 24 |
| 52 | Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1817-1824. | 3.3 | 22 |
| 53 | Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1209-1219. | 3.3 | 22 |
| 54 | In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, N/A. | 3.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Transepithelial transport across the blood–testis barrier. <i>Reproduction</i> , 2018, 156, R187-R194. | 2.6 | 21 |
| 56 | DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4). <i>Drug Metabolism and Disposition</i> , 2004, 32, 1265-1271. | 3.3 | 20 |
| 57 | Minimal Role of Hepatic Transporters in the Hepatoprotection against LCA-Induced Intrahepatic Cholestasis. <i>Toxicological Sciences</i> , 2008, 102, 196-204. | 3.1 | 20 |
| 58 | Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 241-248. | 12.0 | 20 |
| 59 | Identification of a Functional Antioxidant Response Element within the Eighth Intron of the Human <i>ABCC3</i> Gene. <i>Drug Metabolism and Disposition</i> , 2015, 43, 93-99. | 3.3 | 19 |
| 60 | Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1317-1325. | 3.3 | 19 |
| 61 | Selective and Cytokine-Dependent Regulation of Hepatic Transporters and Bile Acid Homeostasis during Infectious Colitis in Mice. <i>Drug Metabolism and Disposition</i> , 2014, 42, 596-602. | 3.3 | 18 |
| 62 | Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. , 2015, 151, 99-106. | | 18 |
| 63 | Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat. <i>Toxicological Sciences</i> , 2014, 142, 105-116. | 3.1 | 17 |
| 64 | Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis. <i>Biochemical Pharmacology</i> , 2016, 122, 62-71. | 4.4 | 16 |
| 65 | Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice. <i>Toxicology Letters</i> , 2009, 188, 38-44. | 0.8 | 15 |
| 66 | Renal Xenobiotic Transporter Expression is Altered in Multiple Experimental Models of Nonalcoholic Steatohepatitis. <i>Drug Metabolism and Disposition</i> , 2015, 43, 266-272. | 3.3 | 15 |
| 67 | Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2. <i>Drug Metabolism and Disposition</i> , 2020, 48, 603-612. | 3.3 | 15 |
| 68 | Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling. <i>Molecular Pharmacology</i> , 2021, 99, 147-162. | 2.3 | 15 |
| 69 | Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. <i>Toxicon</i> , 2019, 162, 1-8. | 1.6 | 13 |
| 70 | Induction of drug metabolism enzymes and transporters by oltipraz in rats. <i>Journal of Biochemical and Molecular Toxicology</i> , 2008, 22, 128-135. | 3.0 | 12 |
| 71 | Organic and inorganic transporters of the testis: A review. <i>Spermatogenesis</i> , 2014, 4, e979653. | 0.8 | 12 |
| 72 | <sc>PF</sc>–07321332 (Nirmatrelvir) does not interact with human <sc>ENT1</sc> or <sc>ENT2</sc>: Implications for <sc>COVID</sc>–19 patients. <i>Clinical and Translational Science</i> , 2022, 15, 1599-1605. | 3.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. <i>Journal of Biochemical and Molecular Toxicology</i> , 2018, 32, e22035. | 3.0 | 11 |
| 74 | Genetic variation in the mouse model of Niemann Pick C1 affects female, as well as male, adiposity, and hepatic bile transporters but has indeterminate effects on caveolae. <i>Gene</i> , 2012, 491, 128-134. | 2.2 | 10 |
| 75 | Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression. <i>Drug Metabolism and Disposition</i> , 2016, 44, 518-526. | 3.3 | 10 |
| 76 | Generation of a hTERT-Immortalized Human Sertoli Cell Model to Study Transporter Dynamics at the Blood-Testis Barrier. <i>Pharmaceutics</i> , 2020, 12, 1005. | 4.5 | 10 |
| 77 | Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir. <i>Biochemical Pharmacology</i> , 2016, 115, 144-151. | 4.4 | 9 |
| 78 | Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 246-253. | 2.5 | 9 |
| 79 | Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1. <i>Drug Metabolism and Disposition</i> , 2021, 49, 479-489. | 3.3 | 9 |
| 80 | Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier. <i>Drug Metabolism and Disposition</i> , 2022, 50, 770-780. | 3.3 | 9 |
| 81 | Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. <i>Journal of Biochemical and Molecular Toxicology</i> , 2008, 22, 93-100. | 3.0 | 8 |
| 82 | Xenobiotic transporter expression along the male genital tract. <i>Reproductive Toxicology</i> , 2014, 47, 1-8. | 2.9 | 8 |
| 83 | Altered Hepatic Transport by Fetal Arsenite Exposure in Diet-Induced Fatty Liver Disease. <i>Journal of Biochemical and Molecular Toxicology</i> , 2016, 30, 321-330. | 3.0 | 8 |
| 84 | Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3869-3878. | 12.0 | 7 |
| 85 | Gene-by-Environment Interaction of Bcrp ^{+/+} and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1478-1486. | 3.3 | 6 |
| 86 | Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity. <i>Drug Metabolism and Disposition</i> , 2021, , DMD-MR-2021-000451. | 3.3 | 6 |
| 87 | Localization of nucleoside transporters in rat epididymis. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, e21911. | 3.0 | 5 |
| 88 | Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations. <i>Drug Metabolism and Disposition</i> , 2022, 50, 492-499. | 3.3 | 5 |
| 89 | Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination. <i>Toxicological Sciences</i> , 2022, 189, 62-72. | 3.1 | 5 |
| 90 | Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00831. | 2.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. <i>Toxicology and Applied Pharmacology</i> , 2019, 368, 49-54. | 2.8 | 3 |
| 92 | ToxPoint: Implications of Species Differences in Function and Localization of Transporters at the Blood-Testis Barrier. <i>Toxicological Sciences</i> , 2021, 181, 1-2. | 3.1 | 3 |
| 93 | Measuring Altered Disposition of Xenobiotics in Experimental Models of Liver Disease. <i>Current Protocols in Toxicology</i> / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2012, 52, Unit 23.1.. | 1.1 | 2 |
| 94 | Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance. <i>Biochemical Pharmacology</i> , 2020, 174, 113780. | 4.4 | 2 |
| 95 | Cell Model for Studying Nucleoside Transporters, a Key Component of the Blood-Testis Barrier. <i>FASEB Journal</i> , 2019, 33, 507.12. | 0.5 | 1 |
| 96 | Role of Lung P450 Oxidoreductase in Paraquat-Induced Collagen Deposition in the Lung. <i>Antioxidants</i> , 2022, 11, 219. | 5.1 | 1 |
| 97 | Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites". <i>Molecular Pharmacology</i> , 2022, 101, 121-122. | 2.3 | 1 |
| 98 | Human Renal Xenobiotic Transporter Expression is Altered in Progression of Non-Alcoholic Fatty Liver Disease as revealed by Quantitative Targeted Proteomics. <i>FASEB Journal</i> , 2021, 35, . | 0.5 | 0 |
| 99 | Renal Transporter Expression Changes in Rodent Models of Nonalcoholic Steatohepatitis. <i>FASEB Journal</i> , 2021, 35, . | 0.5 | 0 |
| 100 | Transporter-mediated mechanism of nucleoside penetration of the blood-testis barrier. <i>FASEB Journal</i> , 2012, 26, 1047.7. | 0.5 | 0 |
| 101 | Mechanistic Basis of Increased Susceptibility to Nephrotoxicants in Chronic Liver Disease. <i>Current Opinion in Toxicology</i> , 2022, , 100347. | 5.0 | 0 |